IC
TENX icon

Ikarian Capital’s Tenax Therapeutics TENX Stock Holding History

Ikarian Capital’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240K Buy
+16,500
New +$211K 0.03% 135

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Ikarian Capital's TENX Position: Q2 2026 in Review

Ikarian Capital reduced its Tenax Therapeutics (TENX) stake by 23% in Q2 2026, selling an estimated $2.94M and leaving 787,600 shares worth $11.5M. The position accounts for 1.23% of the portfolio, ranked #21.

Ikarian Capital first reported a position in TENX in Q3 2021 and has held it in 7 quarters since. The position peaked at $16.3M in Q1 2026. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • Ikarian Capital held 787,600 shares of Tenax Therapeutics worth $11.5M as of Q2 2026.
  • Ikarian Capital sold 230,000 Tenax Therapeutics shares in Q2 2026, an estimated $2.94M.
  • Tenax Therapeutics made up 1.23% of Ikarian Capital's portfolio in Q2 2026, its #21 holding.
  • Ikarian Capital first reported a position in Tenax Therapeutics in Q3 2021 and has held it in 7 quarters since.
  • Ikarian Capital's Tenax Therapeutics position peaked at $16.3M in Q1 2026.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.